Title of Invention

9-SUBSTITUTED MINOCYCLINE COMPOUNDS

Abstract The present invention pertains, at least in part, to novel 9-substituted minocycline confounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Full Text

9 -SUBSTITUTED MINOCYCLINE COMPOUNDS
Related Applications
This application claims priority to U.S. Provisional Patent Application Serial No. 60/275,621, entitled "9-Substituted Minocycline Compounds," filed on March 13, 2001, and U.S. Provisional Patent Application Serial No. 60/216,580, entitled "9-Substituted Minocycline Compounds," filed on July 7, 2000; both of these applications are hereby incorporated herein by reference. This application is related to U.S. Provisional Application Nos. 60/154,701, filed on September 14, 1999; 60/193,972, filed on March 31, 2000; 60/193,879, filed on March 31, 2000; 60/204,158, filed on May 15, 2000; 60/212,030, filed June 16, 2000; and 60/212,471, filed June 16, 2000, the entire contents of each of which are incorporated herein by reference.
Background of the Invention
The development of the tetracycline antibiotics was the direct result of a systematic screening of soil specimens collected from many parts of the world for evidence of microorganisms capable of producing bacteriocidal and/or bacteriostatic compositions. The first of these novel compounds was introduced in 1948 under the name chlortetracycline. Two years later, oxytetracycline became available. The elucidation of the chemical structure of these compounds confirmed their similarity and furnished the analytical basis for the production of a third member of this group in 1952, tetracycline. A new family of tetracycline compounds, without the ring-attached methyl group present in earlier tetracyclines, was prepared in 1957 and became publicly available in 1967; and minocycline was in use by 1972.
Recently, research efforts have focused on developing new tetracycline antibiotic compositions effective under varying therapeutic conditions and routes of administration. New tetracycline analogues have also been investigated which may prove to be equal to or more effective than the originally introduced tetracycline compounds. Examples include U.S. Patent Nos. 2,980,584; 2,990,331; 3,062.717; 3,165,531; 3,454,697; 3.557.280; 3,674,859; 3.957,980;. 4,018^889; 4,024J272; and 4,126,680. These patents are representative of the range of pharmaceutically active tetracycline and tetracycline analogue compositions.
Historically, soon after their initial development and introduction, the tetracyclines were found to be highly effective pharmacologically against rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum. inclusion conjunctivitis, and psittacosis. Hence, tetracyclines became known as "broad spectrum" antibiotics. With the subsequent establishment of their in vitro antimicrobial activity, effectiveness in experimental infections, and pharmacological properties, the tetracyclines as a class rapidly became widely used for therapeutic purposes. However, this widespread use of tetracyclines for both major and minor illnesses and diseases led directly to

the emergence of resistance to these antibiotics even among highly susceptible bacterial species both commensal and pathogenic (e.g., pneumococci and Salmonella). The rise of tetracycline-resistant organisms has resulted in a general decline in use of tetracyclines and tetracycline analogue compositions as antibiotics of choice.
Summary of the Invention
The invention pertains, at least in part, to minocycline compounds of formula I:

wherein:
Xis CHC(R13Y'Y), CR6R6, S,NR6,or O;
R2, R4, R4 , R7' and R7 are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alk}isolfinyl? alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
R4 is NR4 R4 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;
R 9 R , R 5 R and R are each hydrogen or a pro-drug moiety;
R21 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
R and R are indepeiidenily hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyL alkenyl alkynyL aryL alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R9 is nitro, alkyl, alkaayl, alkjuyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkj'l, amino, arylalkenyl, aiylalkynyl, thionitroso, or -(CH2)o-3NR9cC(=Z')ZR9a;
Z is CR9^96, S, NR9b or O;
Z'isNR^OorS;
R93, R9b3 R9c, R9d, R9e and R^ are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
Rs is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, ajkylsulfonyl, alkylamino, or an arylalkyl;

Y* and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and phannaceutically acceptable salts, esters and prodrugs thereof.
The invention also pertains, at legist in part, to 9-substituted minocycline compounds of the formula (II):
wherein:
R4', R4", Rr and Rr are each alkyl; and
R9 is a pyridylethynyl group; an alkenylcarbamate group; a halo group; an alkylacrylate group; a naphthyl group; a haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; a benzofuranyl group; a phenylpropiononeamino group; a tosylamino group; a methoxypyridyl group; an alkeneamino group; an N-t-butyl group; a t-butylamide group; a hydroxybutylamino group; a hydroxypropylamino group; a phenyl group; a iritropGenyl group; a nitrophenyl alkynyl group; an aminophenyl group; an alkoxyphenyl group: a halophenyl urea group; a cyanophenyl group; a carboxyphenyl group; an acylphenyl group; an alkylphenyl group; a halophenyl group; an alkoxyphenyl group; a carboxyalkylphenyl group; a phenylalkynyl group; an alkynyl group; an alkylglycineethylester group; a styrene group; a thiophene group; and an alkylaminophospho group; and phannaceutically acceptable salts, esters and prodrugs thereof.
The invention also pertains to methods of using the minocycline compounds of the invention to treat subjects suffering from states which can treated using the minocycline compounds of the invention.
The invention also pertains to pharmaceutical compositions comprising the minocycline compounds of the invention and a phannaceutically acceptable carrier. The invention also pertains to the use of a minocycline compound of the invention for the manufacture of a medicament, e.g., a medicament for the treatment of a tetracycline responsive state.
Detailed Description of the Invention
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other

known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

"wherein:
X is CHC(R13Y'Y), CR6R6, S, NR6, or O;
R2, R4, R4 , R7 and R7 are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
R4 is NR4 R4 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;
R , R, R 5R and R are each hydrogen or a pro-drug moiety;
R5 is hydroxyL, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl? heteroaromatic, alkyl, alkenyi alkynyL, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carboirvioxy, or aryl carbonyloxy;
R and R are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyL aikenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyi:
R9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arx^lalkynyl, thionitroso, or -(CH2)o-3NR9cC(=Z')ZR9a;
Z is CR9^96, S, NR9b or O;
T is NR*? O or S;
R93, R^, R9c, R9d, R90 and R91 are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocvclic, hetKX>aroxnatic or a prodrug moiety;
R is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthiio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
y and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.
The term minocycline compounds refers to compounds of formula (I) above. In an embodiment, the term minocycline compounds include compounds wherein X is CR R ; R ,

I2', R5, R6, R6', R8, R9, R10, R11, and R12 are each hydrogen; R4 is NR4R4"; and R4', R4", Rr, ind R7" are each lower alkyl, e.g., methyl.
Examples of R9 include substituted and unsubstituted aryl groups. The aryl groups nclude substituted and unsubstituted heteroaryls (e.g., furanyl, imidazolyl, benzothiophenyl, >enzofuranyl? quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, :>enzoimidazolyl, methylenedioxyphenyl, indolyl, tbienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyL, or deazapurinyl), substituted or unsubstituted phenyl, and groups with more than one aromatic ring, such as aaphthyi.
Examples of substituents of R9 include, but are not limited to, alkyl, alkenyl, halogen, bydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, a2ido. heterocyclyl, alkylaryl, aryl and heteroaryl.
In a further embodiment, the aryl R9 group is substituted with one or more substituents such as, for example, carboxylate, alkyl, alkenyl, alkynyl, aryl, heterocyclic, cyano, ammo, halogen, alkoxy, alkoxycarbonyl, amido, alkylcarbonyl, or nitro.
In another embodiment, R9 is substituted or unsubstituted alkynyl. The alkynyl R9 group may be substituted with a substituted or unsubstituted aryl group, such as, for example, phenyl. The possible substituents for the substituted phenyl group include, for example, those listed supra, for the aryl R9 group. Furthermore, the substituted alkynyl R9 group may be substituted with a heteroaryl (e.g., pyridinyl), alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyi, cyclopropyi, cyclobutyL, cyclopentyl, cyclohexyl, etc.), alkenyl (e.g, ethenyl, propenyl, butenyL pentenyl, hexenyl. etcX carboxylate, silyl (e.g., trialkylsilyl, e.g., trimethylsilyl), aralkyL or a alkyloxycarbonyl group.
Each of these groups may also be further substituted, with such substituents as alkyl, alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacafbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterc yclyl, alkylaryl, aryl and heteroaryl.

In a further embodiment, the alkynyl R9 group is substituted with an aminoalkyl group. The aminoalkyl group may then also be substituted with, for example, an alkyl, alkenyl, alkynyl, acyl, carbonyl, or alkylsulfone group.
In another further embodiment, the alkynyl R9 group is substituted with a cycloalkenyl group, such as, for example, cyclopentene.
In another embodiment, R9 is alkyl. The alkyl group may be substituted or unsubstituted. Examples of alkyl groups include, for example, both straight chain, branched and cyclic alkyl groups. For example, alkyl groups include methyl, ethyl, i-propyL n-propyl, i-butyl, n-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. Cyclic alkyl groups include groups with one or more rings, such as, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, etc. In an embodiment, the alkyl R9 group is 2-cyclopentylethyl.
Examples of substituents of alkyl groups include, for example, halogens (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy, perfluoromethoxy, perchloromethoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyL, alkenylaminocarbonyl, carboxy, alkylcarbonyl, arylcarbonyl, arylalkvicarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, arninocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulihydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, alkenyl, sulfonato, sulfamoyl, sulfonarnido, nitro, alkenyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
In another embodiment, the minocycline compound of the invention is a compound wherein R9 is ^fR9cC(=Z')ZR9a, -CH2NR9cC(=Z')ZR9a5 H;CH2)2NR9cC(=Z')ZR9a, or -(CH2)3 NR^C^Z^ZR92. In certain embodiments, R9 is -NR9cC(=Z')ZR9a or -CH2NR9cC(=Z')ZR9a. Examples of R9c include hydrogen- V may be, for example, S, NH, or O. Examples of Z include NR% (e.g., when R9b is hydrogen, alkyl, etc.), O or S.
Examples of R9*1 groups include aryl groups such as substituted and unsubstituted phenyL Examples of possible substituents of aryl R9a groups include, but are not limited to, alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, perfluormethyl, perchloroethyl, etc.), alkenyl, halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy (e.g., methoxy, ethoxy, propoxy, perfluoromethoxy, perchloromethoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato,

sulfamoyl, sulfonamido, nitro, acetyl, alkyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl groups.
In certain embodiments, at least one of the substituents of the substituted phenyl is nitro, alkoxy {e.g., methoxy, methylenedioxy, perfluoromethoxy) alkyl (e.g., methyl, ethyl, propyl, butyl, orpentyl), acetyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), or amino (e.g., dialkylamino). In certain embodiments, the alkoxy group is perhalogenated, e.g., perfluoromethoxy.
Examples of aryl R9a groups include, but are not limited to, unsubstituted phenyl, para-introphenyi,para-methoxy phenyl, />ara-perfiuoromethoxy phenyl, para-acetyl phenyl, 3, 5-methylenedioxyphenyl, 3,5-diperfluoromethyl phenyl, para-bromo phenyl, para-c]Aoxo phenyl, end para-fhxoro phenyl.
Other examples of aryl R9a groups include substituted and unsubstituted heterocycles (e.g., furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, pyrolidinyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl) and substituted and unsubstituted biaryl groups, such as naphthyl and fluorene.
R9* also may be substituted or unsubstituted alkyl, e.g., methyl, ethyl, propyl, butyl, pentyL etc. Examples of substituents include but are not limited to halogens (e.g., fluorine, bromine, chlorine, iodine, etc.), hydroxyl, alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acyiamino, amidmo, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkenyi heterocyclyl, alkylaryl, aryl and heteroaryl.
R9* also can be substituted or unsubstituted alkenyl. Examples of substituents for ^ alkenyl R93 groups include those listed above for alkyl R9a groups. Examples of alkenyl R9a groups include pent-1-enyl.
In an embodiment, Z' is NH, Z is NH? and R?a is alkyl.
The invention also pertains to compounds wherein R9 is aminoalkyl (e.g., aminomethyl). Aminoalkyl R9 groups may be further substituted. Examples of substituents include aryl groups, such as, for example substituted or unsubstituted phenyl (e.g., methylenedioxyphenyl or j?ara-perfluoromethoxyphenyl), or heteraromatic groups which allows the compound of the invention to perform its intended function.




Pharmaceutically acceptable salts of these compounds are also included. Other compound of the invention are listed in Table 1.
The invention also relates, at least in part, to 9-substituted minocycline compounds of
the formula:
wherein:
R4'5 R4\ Rr, and Rr are each alkyl; and
R9 is apyridylethynyl group; an alkenylcarbamate group; a halo group; an alkylacrylate group; anaphthyl urea group; a haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; a benzofuranyl group; a phenylpropiononeamino group; a tosylamino group; a methoxypyridyl group;- an alkeneamino group; anN-t-butyl group; a t-butylamide group; a hydroxybutylamino group; a hydroxypropylamino group; a phenyl group; a nitrophenyl group; a nitrophenyl alkynyl group; an aminophenyl group; a halophenyl urea group; an alkoxyphenyl group; a cyanophenyl group; a carboxyphenyl group; an acylphenyl group; an alkylphenyl group; a halophenyl group; an alkoxyphenyl group; a carboxyalkylphenyl group; a phenylalkynyl group; an alkynyl group; an alkylglycineethylester gfoup; a styrene group; a thiophene group; an alkylaminophospho group; and pharmaceutically acceptable salts thereof

The term !l 9-substituted minocycline compound" includes minocycline compounds with a substituent at the 9 position. In another embodiment, the compound is a derivative of minocycline.
In an embodiment, R is an alkenylcarbamate group. Examples of tetracyciine compounds with this R9 substituent include 9-isopropenyl carbamate minocycline.
In an embodiment, R9 is a pyridylethynyl group. Examples of tetracyciine compounds with this R9 substituent include 9-(2-pyridylethynyl) minocycline.
In an embodiment, R9 is a halo group. Examples of tetracyciine compounds with this S: substituent include 9-iodo minocycline.
In an embodiment, R9 is an alkylacrylate group. Examples of tetracyciine compounds with this R9 substituent include 9-butylacrylate minocycline.
In an embodiment, R9 is a naphthyl urea group. Examples of tetracyciine compounds with this R9substituent include 9-naphthyl minocycline urea.
In an embodiment, R is a haloacetyl group. Examples of tetracyciine compounds with this R9 substituent include 9-chloroacetyl minocycline urea.
In an embodiment R9 is an alkyl carbamate group. Examples of tetracyciine compounds with this R9 substituent include 9-neopentyl minocycline carbamate.
In an embodiment, R9 is a cyclopentyl or cyclopentenyl group. Examples of tetracyciine compounds with this R9 substituent include 9-cyclopentene minocycline.
In an embodiment, R9 is a benzofuranyl group. Examples of tetracyciine compounds with this R5 substituent include 9-benzofuranyl minocycline.
In an embodiment, R9 is a phenylpropiononeamino group. Examples of tetracyciine compounds with this R9 substituent include 9-(phenylpropiononeamino) minocycline.
In an embodiment, R9 is a tosylamino group. Examples of tetracyciine compounds with this R9 substituent include 9-tosylamino minocycline.
In an embodiment, R9 is a methoxypyridyl group. Examples of tetracyciine compounds with this R5 substituent include 9-(2-methoxy-3-pyridyl) minocycline.
In an embodiment, R° is an alkeneamino group. Examples of tetracyciine. compounds with this R9 substituent include 9-(N-2T-hydroxydecyl-9l-ene-amino) minocycline.
In an embodiment, R9 is an N-t-butyl group. Examples of tetracyciine compounds with this R9 substituent include N-t-butyl-minocycline HC1.
In an embodiment, R9 is a t-butylamide group. Examples of tetracyciine compounds with this R9 substituent include 9-BOC-NH minocycline.
In an embodiment, R9 is a hydroxybutylamino group. Examples of tetracyciine compounds with this R9 substituent include 9-(N-2-hydioxybutylamino) minocycline.

In an embodiment, R is a hydroxypropylamino group. Examples of tetracycline compounds with this R9 substituent include 9-(N-3-chloro, 2-hydroxylpropylamino) minocycline.
In an embodiment, R9 is a phenyl group. Examples of tetracycline compounds with this R9 substituent include 9-phenyl minocycline HC1 and 9-p-tolyl minocycline.
In an embodiment, R9 is a nitrophenyl group. Examples of tetracycline compounds with this R substituent include 9-(3'-nitrophenyl) minocycline.
In an embodiment, R9 is a nitrophenyl alkynylgroup. Examples of tetracycline compounds with this R9 substituent include 9-(4'-nitrophenylethynyl) minocycline.
In an embodiment, R9 is an aminophenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(3 -aminophenyl) minocycline.
In an embodiment, R9 is a halophenyl urea group;. Examples of tetracycline compounds with this R9 substituent include 9-(4-chloro,2-trifluoromethylphenyl) minocycline urea.
In an embodiment, R is an alkoxyphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(p-methoxyphenyl) minocycline, 9-(4'-methoxyphenyl) minocycline, and 9-(3.4-methylenedioxyphenyl) minocycline.
In an embodiment, R9 is a cyanophenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(4'-cyanophenyl) minocycline.
In an embodiment, R9 is a carboxyalkylphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(4'-carboxyphenyl) minocycline.
In an embodiment, R9 is an acylphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(3-formylphenyl) minocycline.
In an embodiment, R9 is an alkylphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(4'-t-butylphenyl) minocycline.
In an embodiment, R9 is a halophenyl group. Examples of tetracycline compounds with this R9 substituent include 9-{3-chlorophenyl) minocycline, 9-(2I,4'-difluorophenyI) minocycline, 9-(3,4-difluorophenyl) minocycline, 9-(4'-chlorophenyl) minocycline, 9-(3,4-^ dichlorophenyl) minocycline, and 9-(4l-trifluoromethylplienyl) minocycline.
In an embodiment, R9 is an alkoxyphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(3-ethoxyphenyl) minocycline.
In an embodiment, R9 is a carboxyalkylphenyl group. Examples of tetracycline compounds with this R9 substituent include 9-(4-carboxymethylphenyl) minocycline.
In an embodiment, R9 is a phenylalkynyl group. Examples of tetracycline compounds with this R9 substituent include 9-(phenylethynyl) minocycline, 9~(3-hydroxyphenylethynyl) minocycline, 9-(p-tolylethynyl) minocycline, and 9-(p-methoxyphenylethynyl) minocycline.

In an embodiment, R9 is.an alkynyl group. Examples of tetracycline compounds with this R9 substituent include 9-ethynyl minocycline, 9-(p-fluoroethynyl) minocycline, 9-(trimethylsilylethynyl) minocycline, 9-(propionyl) minocycline, 9-(cyclohexenylethynyl) minocycline, and 9-(l-cyclohexyl-l-hydroxyethynyI) minocycline.
In an embodiment, R9 is an alkylglycineethylester group. Examples of tetracycline compounds with this R9 substituent include 9-propylglycineethylester minocycline HC1, and 9-methylglycineethylester minocycline.
In an embodiment, R9 is a styrene group. Examples of tetracycline compounds with mis R9 substituent include 9-(styrene) minocycline, 9-(4'-fluorostyrene) minocycline.
In an embodiment, R9 is a thiophene group. Examples of tetracycline compounds with this R9 substituent include 9-(2-thiophene) minocycline, and 9-(5t-chloro-2l-thiophene) minocycline.
In an embodiment, R9 is an alkylaminophospho group. Examples of tetracycline compounds with this R9 substituent include 9»(p-methoxyphenylaminophospho) minocycline, and 9-(phenylaminophospho) minocycline.
The minocycline compounds of this invention can be synthesized using the methods described in Schemes 1-6.
9-substituted minocyclines can be synthesized by the following general method, shown in Scheme 1.

.c ID
SCHEME 1
Generally, 9-substituted minocycline compounds can be synthesized as shown in Scheme 2 by treating minocycline (1 A), with sulfuric acid and sodium nitrate. The resulting product is 9-nitro (IB) minocycline. The nitro minocycline compound is then treated with hydrogen gas and a platinum catalyst to yield the 9-amino minocycline compound, 1C. To synthesize 9 derivatives, the 9-amino minocycline compound is treated with HONO, to yield tbe diazonium salt (ID). The salt can subsequently be treated with numerous compounds

possessing an alkene or n bond functional group such as alkenes, aryls, and alkynyls (e.g., R^r) yielding the 9-substituted minocycline compound (IE).

As siiown in Scheme 3, minocycline compounds of the invention wherein R9 is a carbamate or a urea derivative can be synthesized using the following protocol. Minocycline (2A) is treated with NaNC>2 under acidic conditions forming 9-nitro minocycline (2B). 9-nitrominocycline (2B) is then treated with H2 gas and a platinum catalyst to form the 9-amino miuocycline derivative (2C). To form the urea derivative (2E), isocyanate (2D) is reacted with the 9-amino minocycline derivative (2C). To form the carbamate (2G), the appropriate acid chloride ester (2F) is reacted with 2C.


As shown in Scheme 3, minocycline compounds of the invention, wherein R9 is a heterocyclic (i.e. thiazole) substituted amino group can be synthesized using the above protocol. 9-axnino minocyline (3A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C). The protected thiourea (3C) is then deprotected yielding the active tetracycline urea or tetracycline thiourea (3D) compound. The tetracycline thiourea (3D) is reached with an a-haloketone (3E) to produce a thiazole substituted 9-amino minocycline (3F).

As shown in Scheme 4, 9- alkenyl minocycline compounds (4A) can be hydrogenated to form alkyl 9- substituted minocycline compounds (4B). Scheme 4 depicts the selective hydrogenation of the 9- position double bond, with hydrogen gas and a palladium/carbon catalyst Similarly, 9-alkynyl minocyclines also can be hydrogenated to form 9-alkyl minocycline compounds.

In Scheme 5, a general synthetic scheme for synthesizing 9-position aryl derivatives of a minocycline compound is shown. In Scheme 5, a Suzuki coupling of an aryl boronic acid with an iodominocycline compound is shown. An iodo minocycline compound (5B) can be synthesized from sancycline by treating minocycline (5 A) with at least one equivalent N-i6dosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 9-

iodo minocycline (5B) can then be purified using standard techniques known in the art To form the aryl derivative, 9-iodo minocycline (5B) is treated with boronic acid (5C) plus aqueous sodium carbonate, and is catalyzed with palladium. The product (5D) can be purified by methods known in the art (such as HPLC). Other 9-aryl minocycline compounds can be synthesized using similar protocols.
The 9-substituted minocycline compounds of the invention can also be synthesized using Stille cross couplings. Stille cross couplings can be performed using an appropriate tin reagent (e.g., R-S11BU3) and a halogenated tetracycline compound, (e.g., 9-iodominocycline). Tlie tin reagent and the iodominocycline compound can be treated with a palladium catalyst (e.g., Pd(PPh3)2Cl2 or Pd(AsPh3)2Cl2) and, optionally, with an additional copper salt, e.g., CuL The resulting compound can then be purified using techniques known in the art.

SCHEME 6
The compounds of the invention can also be synthesized using Heck-type cross coupling reactions. As shown in Scheme 6, Heck-type cross-couplings can be performed using a halogenated tetracycline compound (e.g., 9-iodominocycline, 6A), a reactive alkene (6B) or alkyne (6D). and an appropriate palladium or other transition metal catalyst. The resulting 9- ■ substituted alkenyl (6C) or 9-substituted alkynyl (6E) minocycline compound can then be purified using techniques known in the art.
The term "alky!" includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched cl?ain alkyl has 6 or fewer carbon atoms in its backbone (e.g., CpCe for straight chain, C3-C6 for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have

from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term Ci-Ce includes alkyl groups containing 1 to 6 carbon atoms.
Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryk>xycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaininocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyL, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, aryicarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido., nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" or an "arylalkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes the side chains of natural and unnatural amino acids.
The term "aryl" includes groups, including 5- and 6-membered single-ring aromatic groups feat may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furarL thiophene, thiazole. isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole. pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles*. "heterocycles," "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocafbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aryialkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, aiylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a poly cycle (e.g., tetralin).

The term "alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups wMeh include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., Co-Cg for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term Cx-C$ includes alkenyl groups containing 2 to 6 carbon atoms.
Moreover, the term alkenyl includes both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, axykarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyL alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocafbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino. dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkyterbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, aiylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitre, trifluoromethyL cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
The term "alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond." For example, the term "alkynyl" includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyL, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e-g-> C2-C6 for straight chain, C3-C6 for branched chain). The term C2-C6 includes alkynyl groups containing 2 to 6 carbon atoms.
Moreover, the term alkynyl includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a

hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcaibonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carb.oxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, aBcyffliJo, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyL sulfonamido, nitro, rdfluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms.
The term "acyl" includes compounds and moieties which contain the acyl radical (CH3CO-) or a carbonyl group. The term "substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogecs, hyckoxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbcnrvioxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyL dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, pbosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates. alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, triflroromethyi, cyano. azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
The tenn "acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term inclxides alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
The term "aroyl" includes compounds and moieties with an aryl or heteroaromatic
moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl
carboxy, etc. • ■
The terms "alkoxyalkyl", "alkylaminoalkyl" and "thioalkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, etfroxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy

groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyL, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarix>nylamino, aiylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkyMzio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluorometiiyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties- Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.
The term "amine" or "amino" includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term "alkyl amino" includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term "dialkyl ammo" includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The team "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term "alkylarylamino," "alkylaxninoaryF or "arylaminoalkyl" refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term "alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
The term "amide" or "aminocarbonyl" includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes "alkaminocarbonyl" or "alkylammocarbonyl" groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an ammo group bound to a carbonyl group. It includes arylaminocatbonyl groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms "alkyiammocaixrayy" "alkenylaminocarbonyl," "alkynylaminocarbonyl," "arylaminocarbonyl," "alkylcarbonylamino," "alkenylcarbonylamino," "alkynylcarbonylamino," and "arylcarbonylamino" are included in term "amide." Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
The term "carbonyl" or "carboxy" includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
The term 'thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.

The term "ether" includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl" which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.
The term "ester" includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycaibonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl groups are as defined above.
The term "thioether" includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" and alkthioalkynyls'5 refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
The term "hydroxy" or "hydroxyl" includes groups with an -OH or -O".
The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term "peifcalogenaied" generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
The terms "polycyclyl" or "polycyclic radical" refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the poiycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyL, alkoxycarbonyl, alkylaminoacarbonyL arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcaibonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.
The term "heteroatom" includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The term "prodrug moiety" includes moieties which can be metabolized in vivo to a hydroxyl group and moieties which may advantageously remain esterified in vivo. Preferably, the prodrugs moieties are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other advantageous groups. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower aJkyl-amino lower-alkyi esters {e.g., dimethylaminoethyl ester), acylamino lower alkyl esters {e.g., acetyloxymethyl ester), acyloxy lower alkyl esters {e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters {e.g., benzyl ester), substituted {e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionoic acid esters and acyl esters.
It will be noted that the structure of some of the minocycline compounds of this inventkni includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry {e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof.
The invention also pertains to methods for treating a tetracycline responsive states in subjects, by administering to a subject an effective amount of a minocycline compound of the invention {e.g., a compound of Formula (I) or shown in Table 1), such that the tetracycline responsive state is treated.
The language "tetracycline compound responsive state" includes states which can b$ treated, prevented, or otherwise ameliorated by the administration of a minocycline compound of the invention. Tetracycline compound responsive states include bacterial infections (including those which are resistant to other tetracycline compounds), cancer, diabetes, and other states for which tetracycline compounds have been found to be active (see, for example, U.S. Patent Nos. 5,789,395; 5,834,450; and 5,532,227). Compounds of the invention can be used to prevent or control important mammalian and veterinary diseases such as diarrhea, urinary tract infections, infections of skin and skin structure, ear, nose and throat infections, wound infection, mastitis and the like. In addition, methods for treating neoplasms using tetracycline compounds of the invention are also included (van der Bozert et al., Cancer Res.,

48:6686-6690 (1988)). For certain tetracycline responsive state, a minocycline compound of the invention with little or no antibacterial activity may be desirable.
Bacterial infections may be caused by a wide variety of gram positive and gram negative bacteria. The compounds of the invention are useful as antibiotics against organisms which are resistant to other tetracycline compounds. The antibiotic activity of the tetracycline compounds of the invention may be determined using the method discussed in Example 2, or by using the in vitro standard broth dilution method described in Waitz, J.A., National Commission for Clinical Laboratory Standards, Document M7-A2, vol. 10, no. 8, pp. 13-20, 2nd efitkm, Vfflanova, PA (1990).
The minocycline compounds may also be used to treat infections traditionally treated with tetracycline compounds such as, for example, rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, psittacosis. The tetracycline compounds may be used to treat infections of, e.g., K pnevmoniae> Salmonella, E. hirae, A. baumanii, B. cataiThalis, H. influenzae, P. aeruginosa, E. faeciwn, E. coliy S. aureus or E. faecalis. In one embodiment, the minocycline compound is used to treat a bacterial infection that is resistant to other tetracycline antibiotic compounds. The minocycline compound of the invention may be administered with a phannaceatical!y acceptable carrier.
The language "effective amount" of the compound is that ambunt necessary or sufficient to treat or prevent a tetracycline compound responsive state. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular minocycline compound. For example, the choice of the minocycline compound can affect what constitutes an "effective amount11. One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the minocycline compound without undue experimentation.
Hie invention also pertains to methods of treatment against microorganism infections and associated diseases. The methods include administration of an effective amount of one of more minocycliae compounds to a subject The subject can be either a plant or, advantageously, an animaL e.g., a mammal, e.g., a. human.
In the therapeutic methods of the invention, one or more minocycline compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.

The invention also pertains to pharmaceutical compositions comprising a therapeutically effective amount of a mtnocycline compound and, optionally, a pharmaceutically acceptable carrier.
The language "pharmaceutically acceptable carrier" includes substances capable of being coadministered with the minocycline compound(s), and which allow both to perform their intended function, e.g., treat or prevent a tetracycline responsive state. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohoL vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, slock; add, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteiiousty react with the active compounds of the invention.
The minocycline compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of the minocycline compounds of the invention that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinaie, fumaxate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and palmoate [i.e., l,r-med2ylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to a subject, e.g., a mammal, it is often desirable in practice to initially isolate a minocycline compound of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The preparation of other minocycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

The preparation of other minocycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
The minocycline compounds of the invention that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those minocycline compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmaceoticaliy acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. The pharmaceutically acceptable base addition salts of minocycline compounds of the invention that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts may be readily prepared by treating the minocycline compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively 9 a lower alkyl alcohol solution of the minocycline compound of the invention may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
The preparation of other minocycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
The minocycline compounds of the invention and pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in effective dosages, depending upon the weight and condition of the subject being treated and the particular route of administration chosen. -Variations may occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out
The pharmaceutical compositions of the invention may be administered alone or in combination with other known compositions for treating tetracycline responsive states in a subject, e.g., a mammal. Preferred mammals include pets (e.g., cats, dogs, ferrets, etc.), farm animals (cows, sheep, pigs, horses, goats, etc.), lab animals (rats, mice, monkeys, etc.), and primates (chimpanzees, humans, gorillas). The language "in combination with" a known composition is intended to include simultaneous administration of the composition of the mvention and the known composition, administration of the composition of the invention first,

followed by the known composition and administration of the known composition first, followed by the composition of the invention. Any of the therapeutically composition known in the art for treating tetracycline responsive states can be used in the methods of the invention.
The minocycline compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously mentioned, and the administration may be carried out in single or multiple doses. For example, the novel therapeutic agents of this invention can be administered advantageously in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and " various like combinations thereof.
For parenleral administration (including intraperitoneal, subcutaneous, intravenous, intradennal or intramuscular injection), solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in tlje art For parenteral application, examples of suitable preparations include solutions,

preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compounds may be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables.
Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin. Examples of methods of topical administration include transdermal, buccal or sublingual application. For topical applications, therapeutic compounds can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream. Such topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolauriate 5% in water, sodium lauryl sulfate 5% in water, and the like. In addition, materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired.
For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulstion, multiple coatings, etc.
In addition to treatment of human subjects, the therapeutic methods of the invention also will have significant veterinary applications, e.g. for treatment of livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys and the like; horses; and pets such as dogs and cats. Also, the compounds of the invention may be used to treat non-animal subjects, such as plants.
It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions foamulaled. the mode of application, the particular site of administration, etc.^ Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines.
In general, compounds of the invention for treatment can be administered to a subject in dosages used in prior minocycline therapies. See, for example, the Physicians' Desk Reference. For example, a suitable effective dose of one or more compounds of the invention will be in the range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per (Jay, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient

per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
It will also be understood that normal, conventionally known precautions will be taken regarding the administration of minocyclines generally to ensure their efficacy under normal use circumstances. Especially when employed for therapeutic treatment of humans and animals in vivo, the practitioner should take all sensible precautions to avoid conventionally known coi^radictions and toxic effects. Thus, the conventionally recognized adverse reactions of gastrointestinal distress and inflammations, the renal toxicity, hypersensitivity reactions, changes in blood, and impairment of absorption through aluminum, calcium, and magnesium ions should be duly considered in the conventional manner.
In one embodiment the minocycline compounds of the invention do not include those described in U.S. Patent Application Serial No. 09/823,884, incorporated herein by reference.
Furthermore, the invention also pertains to the use of a minocycline compound of formula I or II, for the preparation of a medicament. The medicament may include a pharmaceutically acceptable carrier and the minocycline compound is an effective amount, e.g., an effective amount to treat a tetracycline responsive state.
EXEMPLIFICATION OF THE INVENTION
Compounds of the invention may be made as described below, with modifications to the procedure below within the skill of those of ordinary skill in the art.
Example 1: Preparation of Minocycline Compounds of the Invention
Preparation of 9-Iodominocyclme
To 200ml of 97% methanesulfonic acid was slowly added, at ambient temperature, portionwise [30gJ>6.56mM] of minocycline«Z>iy-hydrochloride salt. The dark yellow brown" solution was then stirred at ambient temperature while [38g;169.7mM] of N-iodosuccinimide was added, in six equal portions, over 3.0 hours time. The reaction was monitored via analytical LC, noting the disappearance of the starting material.
The reaction was slowly quenched into 2L of ice cold water containing [17.88g;1134.1mM] of sodium thiosulfate with rapid stirring. This quench was stirred for approximately 30 minutes at ambient temperature. The aqueous layer was then extracted with 6x200ml of ethyl acetate before the aqueous was poured onto [259.8g;3.08M] of sodium hydrogen carbonate containing 300ml of n-butanol. The phases were split and the aqueous extracted with 4x250ml of n-butanol. The organic fractions were combined and washed with 3x250ml of water and once with 250ml of saturated brine. The resulting organic phase was

reduced to dryness under reduced pressure. The residue was suspended in methanol (~~600mI) and anhydrous HC1 gas was bubbled into this mixture until solution occurred This solution was reduced to dryness under reduced pressure. The filtrates were reduced to dryness under reduced pressure. The resulting material was triturated with 300ml of methyl t-butyl ether and isolated via filtration. This material was redissolved in 300ml of methanol and treated with 0.5g of wood carbon, filtered and filtrates reduced to dryness under reduced pressure. The material was again powdered under methyl t-butyl ether, isolated via suction filtration and washed with more ether, and finally hexanes. The material was vacuum dried to give 22.6g of a light yellow brown powder.
General Procedure For Preparation of 9-Alkynyl Minocycline Compounds
1 mmol 9-iodo minocycline, 50mg tetrakis tripenylphosphinato palladate, 12 mg palladium acetate, 32mg copper (I) iodide are dissolved/suspended in 10ml acetonitrile. 2 to 5ml triethylamine and 3 to 5 mmol alkynyl derivative is added. The reaction mixture is vigorously stirred between ambient temperature to 70°C The reaction time is 2-24 hours. When the reaction is completed the dark suspension is filtered through a celite bed and concentrated. The crude product is purified by prep HPLC. The combined fractions are concentrated and taken up in —lml methanol.. —3ml HC1 saturated methanol is added, and the product is precipitated with ether.
General Procedure For Preparation of 9-Aryl Minocyclipe Compounds
0.15mmol,of 9-iodominocycline, PdOAc (3.2mg), 229pi 2M Na2CC>3 and 2 equivalents of phenyl boronic acid were dissolved/suspended in 10ml methanol. The reaction flask was purged with argon and the reaction run for a minimum of four hours or until HPLC monitoring shows consumption of starting material and/or the appearance of products. The suspension was filtered through celite, and subject to purification by prep HPLC on a divinylbenzene column.


To 3 mL of dimethylformamide was added 150 mg (0.25 mmol) of 9-methyl aminominocyline trihydrochloride and 67 mL (0.50 mmol) of triethylamine at 25 °C. With stirring, 75 mL (0.50 mmol) of 4-trifluoromethoxyphenylisocyanate was added and the resulting reaction mixture was stirred at 25 °C for two hours. The reaction was monitored by analytical HPLC (4.6 x 50mm reversed phase Luna C18 column, 5 minute linear gradient 1-100% B buffer, A buffer was water with 0.1% trifluoroacetic acid, B buffer was acetonitrile with 0.1% trifluoroacetic acid). Upon completion, the reaction was quenched with 1 mL of water and fee pH adjusted to approximately 2.0 with concentrated HC1. The solution was filtered and the compound purified by preparative HPLC. The yield of compound OU was 64 mg (37% yield). The purity of Compound OU was 95% determined by LCMS (M+l = 690).

In a clean, dry reaction vessel, was placed 9-iodominocycline [500mg; 0.762mmoles]bis HC1 salt, palladium (II) acetate [17.2mg; 0.076mmoles] along with 10ml of reagent grade methanol. The solution was immediately purged, with stirring, with a stream of argon gas for approximately 5 minutes. The reaction vessel was brought to reflux and to it was sequentially added via syringe 2M potassium carbonate solution [1.91ml; 3.81mmoles], followed by a solution of p-carboxyphenyl boronic acid [238.3mg; 1.53mmoles]in 5ml of reagent DMF. Both, of these solutions were previously degassed with argon gas for approximately 5mimites. The reaction was heated for 45 minutes, the progress was monitored via reverse phase HPLC. The reaction was suctioned filtered through a pad of diatomaceous earth and washed the pad with DMF. The filtrates were reduced to an oil under vacuum and^ residue treated with t-butylmethyl ether. Crude material was purified via reverse phase HPLC on DVB utilizing a gradient of water and methanol/acetonitrile containing 1.0% trifluoroacetic acid. Product confirmed by mass spectrum: found M+l 578.58; the structure corroborated with 1HNMR-
Example 2: In vitro Minimum Inhibitory Concentration (MIC) Assay
The following assay is used to determine the efficacy of minocycline compounds against common bacteria- 2 mg of each compound is dissolved in 100 |al of DMSO. The solution is then added to cation-adjusted Mueller Hinton broth (CAMHB), which results in a final compound concentration of 200 \ig per ml. The minocycline compound solutions are

diluted to 50 pL volumes, with a test compound concentration of .098 |xg/ml. Optical density (OD) determinations are made from fresh log-phase broth cultures of the test strains. Dilutions are made to achieve a final cell density of lxlO6 CFU/ml. At OD=1, cell densities for different genera should be approximately:
Rcoli lxl 09 CFU/ml
S. aureus 5x108 CFU/ml
Enterococcus sp. 2.5x109 CFU/ml
50 vl of the cell suspensions are added to each well of microtiter plates. The final cell density should be approximately 5x105 CFU/ml. These plates are incubated at 35 °C in an ambient air incubator for approximately 18 hr. The plates are read with a microplate reader and are visually inspected when necessary. The MIC is defined as the lowest concentration of the minocycline compound that inhibits growth. Compounds of the invention indicate good inhibition of growth.
In Table 1, compounds which were good inhibitors of growth of a particular bacteria are indicated with *, compounds which were very good inhibitors of a particular bacteria are indicated with **, and compounds with were particularly good inhibitors of a particular bacteria are indicated with ***.
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimemation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference. The appropriate components, processes, and raeihods of those patents, applications and other documents may be selected for the present invention and embodiments thereof.



WE CLAIM:
1. A minocycline compound which is effective for the treatment of a tetracycline
responsive state, of the formula I:

R4>; R4", Rr and R7" axe each lower (Cw) alkyl; and R9 is alkyl which is substituted by an araino group, an optionally substituted alkylamino group or ah optionally substituted dialkylamino group,
and pharmaceuticaEy acceptable salts, esters and prodrugs thereof.
2. The minocycline compound of claim 1, wherein R9 is methyl substituted with a
3. substituted or unsubstituted alkylamino or dialkylamino group.
4. The minocycline compound of claim 2, wherein R9 is methyl substituted with an
5. unsubstituted alkyiamiBD group,
4. The minocycline compound of claim 3, wherein said unsubstituted alkylamino
group is pentyiamino.
5. The minocycline compound of claim 2, wherein said alkylamino group is
6. substituted with an aryl group.
7. The minocycline compound of claim 5, wherein said aryl group is substituted or
8. unsubstituted phenyl

7. The compound of claim 1, wherein said compound is selected from the group
consisting of:

or pharmaceutically acceptable salts, esters and prodrugs thereof.
8. The compound of claim 1, wherein said compound is

or phannaceutically acceptable salts, esters and prodrugs thereof.
9. The minocycline compound of claim 1, wherein said minocycline compound is
selected from the group consisting of:




or pharmaceuticaUy acceptable salts, esters and prodrugs thereof.
10. A pharmaceutical composition comprising a therapeutically effective amount of a minocycline compound of any one of claims 1 to 9 and a pharmaceutically acceptable carrier.































Documents:

0944-chenp-2007-abstract.pdf

0944-chenp-2007-assignement.pdf

0944-chenp-2007-claims.pdf

0944-chenp-2007-correspondnece-others.pdf

0944-chenp-2007-description(complete).pdf

0944-chenp-2007-form 1.pdf

0944-chenp-2007-form 26.pdf

0944-chenp-2007-form 3.pdf

944-chenp-2007 amended claims 08-08-2011.pdf

944-CHENP-2007 AMENDED CLAIMS 29-04-2011.pdf

944-CHENP-2007 AMENDED PAGES OF SPECIFICATION 29-04-2011.pdf

944-CHENP-2007 CORRESPONDENCE OTHERS 01-07-2011.pdf

944-chenp-2007 form-3 29-04-2011.pdf

944-CHENP-2007 OTHER PATENT DOCUMENT 29-04-2011.pdf

944-chenp-2007 correspondence others 08-08-2011.pdf

944-CHENP-2007 CORRESPONDENCE OTHERS 03-06-2010.pdf

944-CHENP-2007 EXAMINATION REPORT REPLY RECIEVED 29-04-2011.pdf


Patent Number 248803
Indian Patent Application Number 944/CHENP/2007
PG Journal Number 36/2011
Publication Date 09-Sep-2011
Grant Date 25-Aug-2011
Date of Filing 05-Mar-2007
Name of Patentee TRUSTEES OF TUFTS COLLEGE
Applicant Address BALLOU HALL, 4TH FLOOR, MEDFORD, MA 02155, USA
Inventors:
# Inventor's Name Inventor's Address
1 NELSON, MARK, L 47 BARNSTABLE ROAD, NORFOLK, MA 02056, USA
2 ISMAIL, MOHAMED, Y 5 HUNT ROAD, BEDFORD, MA 01730, USA
3 HONEYMAN, LAURA 27 THORNDIKE STREET, ARLINGTON, MA 02474, USA
4 RENNIE, GLEN 11 CLARK ROAD, SOUTHY WEYMOUTH, MA 02190, USA
5 BHATIA, BEENA 3 BRIAN LANE, MANSFIELD, MA 02048, USA
6 VISKI, PETER 11 KEW COURT, ASHAROKEN, NY 11768, USA
7 DUMORNAY, JIMMY 25 KENDALL STREET, WALPOLE, MA 02081, USA
8 LIU, GUI 73 EDWARD STREET, MEDFORD, MA 02155, USA
9 KOZA, DARRELL 16 LEDWARD AVENUE, WESTERLY, RI 02891, USA
10 SHEAHAN, PAUL 103 HAYDEN ROW STREET, HOPKINTON, MA 01748, USA
11 STAPLETON, KAREN 36 BRADMERE WAY, WEYMOUTH, MA 02191, USA
12 HAWKINS, PAUL 205 WALDEN STREET CAMBRIDGE, MA 02140, USA
13 FRECHETTE, ROGER 40 ESTATE LANE, READING, MA 01867, USA
14 BOWSER, TODD 88 HAGGERTY ROAD, CHARLTON, MA 01507, USA
15 VERMA, ATUL, K 3 BRIAN LANE, MANSFIELD, MA 02048, USA
16 WARCHOL, TAD 411 GREAT ROAD, ACTON, MA 01720, USA
PCT International Classification Number C07C 237/26
PCT International Application Number PCT/US01/20721
PCT International Filing date 2001-06-29
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/216,659 2000-07-07 U.S.A.
2 60/275,621 2001-03-13 U.S.A.